BAUSCH & LOMB ($NYSE:BLCO) released their second quarter of FY2023 earnings results on August 2 2023, with total revenue increasing 10.0% year-over-year to USD 1035.0 million. However, the reported net income of USD -32.0 million was a decrease from the previous year’s net income of USD 5.0 million.
The company reported a decrease in their stock price, with the opening price being $19.2 and the closing price being $18.9, down 2.3% from their previous closing price of $19.4. This decline was a surprise to many investors given the optimism surrounding the company’s recent acquisitions and partnerships, which had been expected to result in an increase in the stock price. This was mainly attributed to the strong performance of their pharmaceutical division, which saw an increase of 17%. Despite the overall increase in revenue, there was some disappointment in the company’s bottom line.
This was mainly due to higher costs associated with their acquisitions and higher taxes, which resulted in a lower net income than many analysts had expected. Overall, BAUSCH & LOMB remains confident in their ability to continue to grow and increase their profitability in the long term. Despite the slight dip in their stock price, investors remain optimistic about the future of the company as they continue to make strategic partnerships and acquisitions. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for BLCO. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for BLCO. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for BLCO. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for BLCO are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – BLCO Intrinsic Stock Value
GoodWhale has conducted an analysis of BAUSCH & LOMB’s wellbeing. After careful consideration, our proprietary Valuation Line has determined that the intrinsic value of BAUSCH & LOMB share is around $16.9. However, we have observed that currently BAUSCH & LOMB stock is traded at $18.9, which is a fair price but slightly overvalued by 11.7%. More…
Risk Rating Analysis
Star Chart Analysis
BAUSCH & LOMB reported their second quarter FY2023 earnings results on August 2 2023. Revenue increased 10.0% year-over-year to USD 1035.0 million, while net income decreased to USD -32.0 million from the same quarter’s USD 5.0 million in the previous year. This marks a major shift for the company, with investors now needing to pay close attention to the company’s performance going forward. BAUSCH & LOMB will need to take steps to reduce expenses and improve profitability in order to appeal to investors.
Additionally, changing consumer trends and competitive pressures must be monitored in order to make informed investing decisions.